Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial ...
Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of ...
Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered ...
Over a year after first agreeing to a reverse merger with Pulmatrix, protein degradation biotech Cullgen has instead opted to be bought by Gyre Therapeutics in a ...
Initiating add-on therapy within 2 years of a myasthenia gravis (MG) diagnosis was associated with a stronger and more consistent clinical response, according to a new study published in the Journal ...
Rallybio Corporation (Nasdaq: RLYB) ("Rallybio") and Candid Therapeutics, Inc. ("Candid"), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager ("TCE") ...
Gilead Foundation today announced a $12 million investment in 33 community?based organizations across 14 states and the District of Columbia through its Community Health Worker (CHW) Comprehensive HIV ...
Researchers are urging more study into whether a surgical procedure called LVA may be repurposed as a potential Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results